Abstracts tagged "Scleroderma"

Abstract Number: 803 • 2016 ACR/ARHP Annual Meeting
Multi-Organ RNA-Sequencing of Systemic Sclerosis (SSc) Patients Shows Reproducible Gene Expression Profiles Across Organ Systems
Bhaven K. Mehta¹, Michael E. Johnson¹, Kimberly A. Archambault¹, Tammara A. Wood², Antonia Valenzuela³, Amanda Crawford⁴, David Fiorentino⁵, Nielsen Fernandez-Becker⁶, Laren Becker⁶, Linda Nguyen⁶, Francesco Boin⁷, Paul Wolters⁸, Lorinda Chung⁹ and Michael Whitfield², ¹Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Stanford University School of Medicine, Stanford, CA, ⁴Dermatology, Stanford University, Redwood City, CA, ⁵Dermatology, Stanford University, Stanford, CA, ⁶Gastroenterology & Hepatology, Stanford University School of Medicine, Palo Alto, CA, ⁷Rheumatology, University California San Francisco, San Francisco, CA, ⁸Pulmonary Division, Department of Medicine, University of California, San Francisco, San Francisco, CA, ⁹Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: While a hallmark of systemic sclerosis (SSc) is skin fibrosis, internal organ involvement is the primary cause of mortality. Pulmonary Arterial Hypertension (PAH), Interstitial…
Abstract Number: 1850 • 2016 ACR/ARHP Annual Meeting
Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc
Tomoya Watanabe¹, Tetsuya Nishimoto², Jonathan Heywood³, Stanley Hoffman⁴, Logan Mlakar⁴ and Carol A. Feghali-Bostwick⁵, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Rheumataology, Medical University of South Carolina, Chareston, SC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: The murine bleomycin (BLM)-induced fibrosis model is the most widely used in systemic sclerosis (SSc) studies. Traditionally, daily subcutaneous injections of BLM for 4-6…
Abstract Number: 1080 • 2015 ACR/ARHP Annual Meeting
Modified Rodnan Skin Score Thresholds for the Optimization of Cohort Enrichment in Clinical Trials in Skin Fibrosis in Patients with Diffuse Cutaneous Systemic Sclerosis
Rucsandra Dobrota¹, Britta Maurer¹, Nicole Graf², Suzana Jordan³, Carmen Marina Mihai⁴, Otylia Kowal-Bielecka⁵, Yannick Allanore⁶, Oliver Distler¹ and EUSTAR co-authors, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²graf biostatistics, Winterthur, Switzerland, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Internal Medicine and Rheumatology, Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ⁶Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France
Background/Purpose: The modified Rodnan skin score (mRSS) is the major outcome measure for skin fibrosis in clinical trials (CT) in diffuse cutaneous scleroderma (dcSSc). Traditionally,…
Abstract Number: 1887 • 2015 ACR/ARHP Annual Meeting
Deficiency in Micronutrients Is a Frequent Burden in Patients with Systemic Sclerosis
Jasmin Laeubli¹, Rucsandra Dobrota¹, Britta Maurer¹, Suzana Jordan², Benjamin Misselwitz³, Mark Fox³ and Oliver Distler¹, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Division of Gastroenterology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Micronutrients are essential dietary factors involved in many metabolic processes, including oxidative stress, collagen synthesis and wound healing, which are key aspects of the…
Abstract Number: 1895 • 2015 ACR/ARHP Annual Meeting
Correlation of Scleroderma Interstitial Lung Disease with Gastroesophageal Reflux
Brady Bulian¹, W Leroy Griffing² and Michael Crowell³, ¹Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, ²Rheumatology, Mayo Clinic Arizona, Scottsdale, AZ, ³Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease involving the skin and visceral organs, most commonly the gastrointestinal tract and lungs. Interstitial lung disease…
Abstract Number: 1912 • 2015 ACR/ARHP Annual Meeting
Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Immune Abnormalities in Animal Models of Systemic Sclerosis
Takashi Yamashita¹, Yoshihide Asano², Takashi Taniguchi¹, Ryosuke Saigusa³, Kouki Nakamura¹, Syunnsuke Miura², Tetsuo Toyama¹, Takehiro Takahashi¹, Yohei Ichimura¹, Ayumi Yoshizaki¹, Maria Trojanowska⁴ and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³7-3-1 Hongo, Bunkyo-ku, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁴Arthritis Center, Boston University, Arthritis Center, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by vasculopathy and fibrosis of the skin and various internal organs. Glycyrrhizin, a triterpenoid saponin…
Abstract Number: 1928 • 2015 ACR/ARHP Annual Meeting
Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis
Shadia Nada¹, Farouk Abu Alhana², Yongqing Wang², Nezam Altorok³ and Bashar Kahaleh⁴, ¹Internal Medicine, Divison of Rheumatology, The University of Toledo, Toledo, OH, ²The University of Toledo, Toledo, OH, ³Internal Medicine, Division of Rheumatology, The University of Toledo, Toledo, OH, ⁴Medicine/Rheumatology, The University of Toledo, Toledo, OH
Background/Purpose: Nearly all patients with Systemic sclerosis (SSc) suffer from vascular dysfunction as illustrated by the uniform presence of Raynaud’s phenomena. The role of vascular…
Abstract Number: 2961 • 2015 ACR/ARHP Annual Meeting
Reliability and Validity of the Total Joint Count and Swollen Joint Count in Early Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Veronica J. Berrocal², Gandikota Girish³, Meng Zhang⁴, Chris Hatzis¹, Shervin Assassi⁵, Elana J. Bernstein⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique E. Hinchcliff⁹, Elena Schiopu¹⁰, Virginia D. Steen¹¹, Tracy M. Frech¹² and Dinesh Khanna¹³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Radiology, University of Michigan, Ann Arbor, MI, ⁴Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Georgetown University Medical Center, Washington, DC, ¹²Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Arthropathy and tendinopathy in Systemic Sclerosis (SSc) contribute to disability and are associated with disease progression. Clinical trials in SSc sometimes include the tender…
Abstract Number: 3136 • 2015 ACR/ARHP Annual Meeting
Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review
Annaliese Tisseverasinghe¹, Ahmad Kadhim², Ambica Parmar², Louis Liu² and Sindhu R. Johnson¹, ¹Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Division of Gastroenterology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: More than 90% of patients with Systemic Sclerosis (SSc) have gastroinstestinal (GI) involvement, commonly dysmotility causing complications such as gastroesophageal reflux and constipation. Treatment…
Abstract Number: 1797 • 2014 ACR/ARHP Annual Meeting
One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
Elana J. Bernstein¹, Eric R. Peterson², Joan M. Bathon² and David J. Lederer², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease…
Abstract Number: 1721 • 2014 ACR/ARHP Annual Meeting
Investigating the SCF/c-Kit Pathway in Scleroderma Fibrosis
Bahja Ahmed Abdi¹, Oseme Etomi², Xu Shiwen¹, David Abraham³, Christopher Denton³ and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Rheumatology, UCL Medical School, London, United Kingdom, ³Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: Stem cell factor (SCF) is a potential driving factor in the development of systemic sclerosis (SSc) and a possible therapeutic target. SCF is a…
Abstract Number: 874 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial
Dinesh Khanna¹, Christopher P. Denton², Jacob M. van Laar³, Angelika Jahreis⁴, Sabrina Cheng⁴, Helen Spotswood⁵, Jeffrey Siegel⁴ and Daniel E. Furst on behalf of FaSScinate Clinical Trial in Patients With SS⁶, ¹University of Michigan Health System, Ann Arbor, MI, ²University College London Medical School, London, United Kingdom, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Genentech, South San Francisco, CA, ⁵Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁶University of California, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis.1,2 IL-6 receptor inhibition prevented and…
Abstract Number: 742 • 2014 ACR/ARHP Annual Meeting
Precision of Ultrasound Skin Thickness Measurements: Influence of Examiner and Ultrasound Transducer
Ingeborg A. Sacksen¹, P. Scott Pollock² and Mark H. Wener³, ¹Rheumatology, University of Washington, Seattle, WA, ²Internal Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ³Rheumatology & Lab Med, University of Washington, Seattle, WA
Background/Purpose Ultrasound has been used to measure scleroderma skin thickness, but it has not been established that routine clinical ultrasound equipment is adequate. We compared skin…
Abstract Number: 746 • 2014 ACR/ARHP Annual Meeting
Elevated Pentraxin 3 in Patients with Systemic Sclerosis: Associations with Vascular Manifestations and Defective Vasculogenesis
Yuichiro Shirai¹, Yuka Okazaki¹, Yumiko Inoue¹, Yuichi Tamura², Hidekata Yasuoka³, Tsutomu Takeuchi¹ and Masataka Kuwana¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Cardiology, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan
Background/Purpose: Pentraxin 3 (PTX3) is a multi-functional pattern recognition protein involved in inflammation, extracellular matrix deposition, and suppression of neovascularization mediated by fibroblast growth factor-2…
Abstract Number: 734 • 2014 ACR/ARHP Annual Meeting
Lower Socioeconomic Status, Male Gender and Diffuse Scleroderma Are Associated with Worse Survival in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Jessica K. Gordon¹, Wei Zhang², Lorinda Chung³, Yan Ma⁴, Virginia D. Steen⁵ and PHAROS Investigators, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Healthcare Research Institute, Hospital for Special Surgery, New York, NY, ³Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Research - Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose Lower socioeconomic status (SES) and male gender have been associated with worse survival in idiopathic pulmonary arterial hypertension (PAH). Pulmonary Hypertension Assessment and Recognition…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].